Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-09), Sonoma Pharmaceuticals's 3-1 Month Momentum % is 32.11%.
The industry rank for Sonoma Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
SNOA's 3-1 Month Momentum % is ranked better than 91.34% of 1028
companies
in the Drug Manufacturers industry
Industry Median: 2.745
vs SNOA: 32.11
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Sonoma Pharmaceuticals 3-1 Month Momentum % Related Terms
SNOA vs GELS, APUS, BTAI: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonoma Pharmaceuticals 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Sonoma Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonoma Pharmaceuticals (SNOA) has a 3-1 Month Momentum % of 32.11% as of Sep. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sonoma Pharmaceuticals and its competitors. According to the industry distribution chart, Sonoma Pharmaceuticals ranks #89 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 8.7%.
Is Sonoma Pharmaceuticals' 3-1 Month Momentum % too high?
Sonoma Pharmaceuticals' current 3-1 Month Momentum % is 32.11%. The Drug Manufacturers industry median 3-1 Month Momentum % is 2.75. Sonoma Pharmaceuticals' value of 32.11% is 1069.8% above this industry median. Based on the distribution chart, Sonoma Pharmaceuticals ranks #89 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sonoma Pharmaceuticals has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sonoma Pharmaceuticals' 3-1 Month Momentum % compare to GELS and APUS?
According to the Drug Manufacturers industry distribution chart, Sonoma Pharmaceuticals ranks #89 out of 1028 companies for 3-1 Month Momentum %. This places Sonoma Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 2.75. Sonoma Pharmaceuticals' value of 32.11% is 1069.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 2.75, based on 1,028 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sonoma Pharmaceuticals's current 3-1 Month Momentum % of 32.11% is 1069.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sonoma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonoma Pharmaceuticals's current 3-1 Month Momentum % is 32.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonoma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sonoma Pharmaceuticals (SNOA) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.52, compared to a current price of $1.30 — trading 14.5% below its estimated fair value. The current 3-1 Month Momentum % is 32.11% and 1069.8% above the Drug Manufacturers industry median of 2.75. Sonoma Pharmaceuticals' overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Sonoma Pharmaceuticals (SNOA), the current 3-1 Month Momentum % is 32.11% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonoma Pharmaceuticals (SNOA) Overvalued in 2026?
Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.30 is trading 14.5% below its estimated GF Value™ of $1.52.
GuruFocus considers Sonoma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SNOA:
3-1 Month Momentum %: 32.11%
GF Value™: $1.52 vs. price of $1.30 (14.5% below fair value)
Industry Position: 1069.8% above the Drug Manufacturers median (#89 of 1028)
No single metric tells the full story. See the SNOA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
45GF Score
Get the complete analysis for SNOA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNOA has been successfully added to your 
